-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
31 ，、《、》，，119，29。，，。，31，、。
It is understood that this adjustment not only includes the above-mentioned 119 drugs in the scope of medical insurance reimbursement, but also closely integrates with the city’s situation.
The reimbursement of drugs for special diseases in outpatient clinics has also been adjusted and improved.
The new drug "Sinimod" has been added.
“Fingolimod” and “Fingolimod” are included in the scope of reimbursement of drugs for outpatient special diseases in “Multiple Sclerosis”; “Amrisentan” is included in the scope of reimbursement of drugs for outpatient special diseases in the “Targeted Treatment of Pulmonary Hypertension”; "Fibrosis anti-fibrosis treatment" is adjusted to "pulmonary interstitial disease anti-fibrosis treatment", and "nintedanib" is included in the "pulmonary interstitial disease anti-fibrosis treatment" outpatient special disease reimbursement.
19 other new drugs including "Zebutinib" have been included in the scope of reimbursement of drugs for special diseases such as malignant tumors in this city.
After the above-mentioned drugs are included in the outpatient special disease reimbursement, the burden of drugs for patients with serious illnesses is greatly reduced.
The reimbursement of drugs for special diseases in outpatient clinics has also been adjusted and improved.
The new drug "Sinimod" has been added.
“Fingolimod” and “Fingolimod” are included in the scope of reimbursement of drugs for outpatient special diseases in “Multiple Sclerosis”; “Amrisentan” is included in the scope of reimbursement of drugs for outpatient special diseases in the “Targeted Treatment of Pulmonary Hypertension”; "Fibrosis anti-fibrosis treatment" is adjusted to "pulmonary interstitial disease anti-fibrosis treatment", and "nintedanib" is included in the "pulmonary interstitial disease anti-fibrosis treatment" outpatient special disease reimbursement.
19 other new drugs including "Zebutinib" have been included in the scope of reimbursement of drugs for special diseases such as malignant tumors in this city.
After the above-mentioned drugs are included in the outpatient special disease reimbursement, the burden of drugs for patients with serious illnesses is greatly reduced.
For example, for the treatment of pulmonary interstitial disease, "Nintanib", before the national implementation of drug negotiations, the average annual drug cost of patients was about 240,000 yuan.
After the country negotiated a substantial price reduction, the average annual drug cost of patients was about 90,000 yuan and was included in the outpatient clinic.
After reimbursement for special diseases, the average annual burden of the drug for retired employees will be further reduced to about 15,000 yuan.
After the country negotiated a substantial price reduction, the average annual drug cost of patients was about 90,000 yuan and was included in the outpatient clinic.
After reimbursement for special diseases, the average annual burden of the drug for retired employees will be further reduced to about 15,000 yuan.
It is understood that since 2001, the city has established an “outpatient special disease” system for patients with serious illnesses who require long-term outpatient treatment and high costs.
The medical expenses incurred in outpatient treatment will be reimbursed in accordance with the hospitalization reimbursement ratio and reimbursement standards .
And only one deductible line is charged within 360 days.
At present, there are 17 kinds of special diseases in outpatient clinics in this city .
The medical expenses incurred in outpatient treatment will be reimbursed in accordance with the hospitalization reimbursement ratio and reimbursement standards .
And only one deductible line is charged within 360 days.
At present, there are 17 kinds of special diseases in outpatient clinics in this city .
At the same time, for drugs successfully negotiated by the state, for long-term outpatient treatment, high cost, and suitable for the treatment of various diseases, in order to further reduce the burden of medical expenses of the masses and facilitate the outpatient treatment of the masses, this city refers to the medical insurance outpatient clinics for urban employees and urban and rural residents.
The reimbursement level of drugs for special diseases will be paid at a fixed proportion for the trial outpatient service of 8 kinds of drugs such as "Klopevir".
The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%.
The reimbursement level of drugs for special diseases will be paid at a fixed proportion for the trial outpatient service of 8 kinds of drugs such as "Klopevir".
The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%.
The Municipal Medical Insurance Bureau pointed out that in order to ensure the benefits of the New Policy and the people, designated medical institutions should transfer in and out of drugs according to the medical insurance drug catalog, and hold pharmaceutical management meetings in a timely manner to adjust and optimize the drug catalog of this medical institution; it should be based on functional positioning.
, Clinical needs and diagnosis and treatment capabilities, etc.
, timely provision and rational use of drugs, and the total amount of medical insurance control, medical institution drug catalog number restrictions, and drug proportions should not be used to affect new drugs, especially the provision of drugs that are successfully negotiated and renewed.
, Use, to ensure that patients can use it and use it well.
, Clinical needs and diagnosis and treatment capabilities, etc.
, timely provision and rational use of drugs, and the total amount of medical insurance control, medical institution drug catalog number restrictions, and drug proportions should not be used to affect new drugs, especially the provision of drugs that are successfully negotiated and renewed.
, Use, to ensure that patients can use it and use it well.
RAM
17 special outpatient diseases
Outpatient treatment of malignant tumors, kidney dialysis, anti-rejection therapy after kidney transplantation, hemophilia, aplastic anemia, anti-rejection therapy after liver transplantation, anti-rejection therapy after liver and kidney transplantation, after heart transplantation Anti-rejection therapy, anti-rejection therapy after lung transplantation, multiple sclerosis, fundus disease intraocular injection therapy, severe psychosis, type C Niemann Pick's disease, moderate to severe allergic asthma biologic therapy, pulmonary interstitial disease resistance Fibrosis treatment, targeted therapy of pulmonary hypertension, multi-drug resistant tuberculosis.
Before the news of medical network on March 1, the Municipal Medical Security Bureau and the Municipal Human Resources and Social Security Bureau jointly issued the "Notice on Adjusting and Regulating the Reimbursement Scope of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs in this Municipality".
In addition, 119 drugs added by the state were included in the city’s medical insurance drug list, and 29 drugs deleted from the national medical insurance drug list were deleted from the city’s medical insurance drug list.
At the same time, the scope of reimbursement for some drugs has been standardized, and the city’s outpatient special disease policy has been improved.
It is reported that the new policy was formally implemented on March 1 and is applicable to urban employees, urban and rural residents and other insured persons in this city.
In addition, 119 drugs added by the state were included in the city’s medical insurance drug list, and 29 drugs deleted from the national medical insurance drug list were deleted from the city’s medical insurance drug list.
At the same time, the scope of reimbursement for some drugs has been standardized, and the city’s outpatient special disease policy has been improved.
It is reported that the new policy was formally implemented on March 1 and is applicable to urban employees, urban and rural residents and other insured persons in this city.
It is understood that this adjustment not only includes the above-mentioned 119 drugs in the scope of medical insurance reimbursement, but also closely integrates with the city’s situation.
The reimbursement of drugs for special diseases in outpatient clinics has also been adjusted and improved.
The new drug "Sinimod" has been added.
“Fingolimod” and “Fingolimod” are included in the scope of reimbursement of drugs for outpatient special diseases in “Multiple Sclerosis”; “Amrisentan” is included in the scope of reimbursement of drugs for outpatient special diseases in the “Targeted Treatment of Pulmonary Hypertension”; "Fibrosis anti-fibrosis treatment" is adjusted to "pulmonary interstitial disease anti-fibrosis treatment", and "nintedanib" is included in the "pulmonary interstitial disease anti-fibrosis treatment" outpatient special disease reimbursement.
19 other new drugs including "Zebutinib" have been included in the scope of reimbursement of drugs for special diseases such as malignant tumors in this city.
After the above-mentioned drugs are included in the outpatient special disease reimbursement, the burden of drugs for patients with serious illnesses is greatly reduced.
The reimbursement of drugs for special diseases in outpatient clinics has also been adjusted and improved.
The new drug "Sinimod" has been added.
“Fingolimod” and “Fingolimod” are included in the scope of reimbursement of drugs for outpatient special diseases in “Multiple Sclerosis”; “Amrisentan” is included in the scope of reimbursement of drugs for outpatient special diseases in the “Targeted Treatment of Pulmonary Hypertension”; "Fibrosis anti-fibrosis treatment" is adjusted to "pulmonary interstitial disease anti-fibrosis treatment", and "nintedanib" is included in the "pulmonary interstitial disease anti-fibrosis treatment" outpatient special disease reimbursement.
19 other new drugs including "Zebutinib" have been included in the scope of reimbursement of drugs for special diseases such as malignant tumors in this city.
After the above-mentioned drugs are included in the outpatient special disease reimbursement, the burden of drugs for patients with serious illnesses is greatly reduced.
For example, for the treatment of pulmonary interstitial disease, "Nintanib", before the national implementation of drug negotiations, the average annual drug cost of patients was about 240,000 yuan.
After the country negotiated a substantial price reduction, the average annual drug cost of patients was about 90,000 yuan and was included in the outpatient clinic.
After reimbursement for special diseases, the average annual burden of the drug for retired employees will be further reduced to about 15,000 yuan.
After the country negotiated a substantial price reduction, the average annual drug cost of patients was about 90,000 yuan and was included in the outpatient clinic.
After reimbursement for special diseases, the average annual burden of the drug for retired employees will be further reduced to about 15,000 yuan.
It is understood that since 2001, the city has established an “outpatient special disease” system for patients with serious illnesses who require long-term outpatient treatment and high costs.
The medical expenses incurred in outpatient treatment will be reimbursed in accordance with the hospitalization reimbursement ratio and reimbursement standards .
And only one deductible line is charged within 360 days.
At present, there are 17 kinds of special diseases in outpatient clinics in this city .
The medical expenses incurred in outpatient treatment will be reimbursed in accordance with the hospitalization reimbursement ratio and reimbursement standards .
And only one deductible line is charged within 360 days.
At present, there are 17 kinds of special diseases in outpatient clinics in this city .
At the same time, for drugs successfully negotiated by the state, for long-term outpatient treatment, high cost, and suitable for the treatment of various diseases, in order to further reduce the burden of medical expenses of the masses and facilitate the outpatient treatment of the masses, this city refers to the medical insurance outpatient clinics for urban employees and urban and rural residents.
The reimbursement level of drugs for special diseases will be paid at a fixed proportion for the trial outpatient service of 8 kinds of drugs such as "Klopevir".
The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%.
The reimbursement level of drugs for special diseases will be paid at a fixed proportion for the trial outpatient service of 8 kinds of drugs such as "Klopevir".
The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%.
The Municipal Medical Insurance Bureau pointed out that in order to ensure the benefits of the New Policy and the people, designated medical institutions should transfer in and out of drugs according to the medical insurance drug catalog, and hold pharmaceutical management meetings in a timely manner to adjust and optimize the drug catalog of this medical institution; it should be based on functional positioning.
, Clinical needs and diagnosis and treatment capabilities, etc.
, timely provision and rational use of drugs, and the total amount of medical insurance control, medical institution drug catalog number restrictions, and drug proportions should not be used to affect new drugs, especially the provision of drugs that are successfully negotiated and renewed.
, Use, to ensure that patients can use it and use it well.
, Clinical needs and diagnosis and treatment capabilities, etc.
, timely provision and rational use of drugs, and the total amount of medical insurance control, medical institution drug catalog number restrictions, and drug proportions should not be used to affect new drugs, especially the provision of drugs that are successfully negotiated and renewed.
, Use, to ensure that patients can use it and use it well.
RAM
17 special outpatient diseases
Outpatient treatment of malignant tumors, kidney dialysis, anti-rejection therapy after kidney transplantation, hemophilia, aplastic anemia, anti-rejection therapy after liver transplantation, anti-rejection therapy after liver and kidney transplantation, after heart transplantation Anti-rejection therapy, anti-rejection therapy after lung transplantation, multiple sclerosis, fundus disease intraocular injection therapy, severe psychosis, type C Niemann Pick's disease, moderate to severe allergic asthma biologic therapy, pulmonary interstitial disease resistance Fibrosis treatment, targeted therapy of pulmonary hypertension, multi-drug resistant tuberculosis.
Before the news of medical network on March 1, the Municipal Medical Security Bureau and the Municipal Human Resources and Social Security Bureau jointly issued the "Notice on Adjusting and Regulating the Reimbursement Scope of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs in this Municipality".
In addition, 119 drugs added by the state were included in the city’s medical insurance drug list, and 29 drugs deleted from the national medical insurance drug list were deleted from the city’s medical insurance drug list.
At the same time, the scope of reimbursement for some drugs has been standardized, and the city’s outpatient special disease policy has been improved.
It is reported that the new policy was formally implemented on March 1 and is applicable to urban employees, urban and rural residents and other insured persons in this city.
In addition, 119 drugs added by the state were included in the city’s medical insurance drug list, and 29 drugs deleted from the national medical insurance drug list were deleted from the city’s medical insurance drug list.
At the same time, the scope of reimbursement for some drugs has been standardized, and the city’s outpatient special disease policy has been improved.
It is reported that the new policy was formally implemented on March 1 and is applicable to urban employees, urban and rural residents and other insured persons in this city.
It is understood that this adjustment not only includes the above-mentioned 119 drugs in the scope of medical insurance reimbursement, but also closely integrates with the city’s situation.
The reimbursement of drugs for special diseases in outpatient clinics has also been adjusted and improved.
The new drug "Sinimod" has been added.
“Fingolimod” and “Fingolimod” are included in the scope of reimbursement of drugs for outpatient special diseases in “Multiple Sclerosis”; “Amrisentan” is included in the scope of reimbursement of drugs for outpatient special diseases in the “Targeted Treatment of Pulmonary Hypertension”; "Fibrosis anti-fibrosis treatment" is adjusted to "pulmonary interstitial disease anti-fibrosis treatment", and "nintedanib" is included in the "pulmonary interstitial disease anti-fibrosis treatment" outpatient special disease reimbursement.
19 other new drugs including "Zebutinib" have been included in the scope of reimbursement of drugs for special diseases such as malignant tumors in this city.
After the above-mentioned drugs are included in the outpatient special disease reimbursement, the burden of drugs for patients with serious illnesses is greatly reduced.
The reimbursement of drugs for special diseases in outpatient clinics has also been adjusted and improved.
The new drug "Sinimod" has been added.
“Fingolimod” and “Fingolimod” are included in the scope of reimbursement of drugs for outpatient special diseases in “Multiple Sclerosis”; “Amrisentan” is included in the scope of reimbursement of drugs for outpatient special diseases in the “Targeted Treatment of Pulmonary Hypertension”; "Fibrosis anti-fibrosis treatment" is adjusted to "pulmonary interstitial disease anti-fibrosis treatment", and "nintedanib" is included in the "pulmonary interstitial disease anti-fibrosis treatment" outpatient special disease reimbursement.
19 other new drugs including "Zebutinib" have been included in the scope of reimbursement of drugs for special diseases such as malignant tumors in this city.
After the above-mentioned drugs are included in the outpatient special disease reimbursement, the burden of drugs for patients with serious illnesses is greatly reduced.
For example, for the treatment of pulmonary interstitial disease, "Nintanib", before the national implementation of drug negotiations, the average annual drug cost of patients was about 240,000 yuan.
After the country negotiated a substantial price reduction, the average annual drug cost of patients was about 90,000 yuan and was included in the outpatient clinic.
After reimbursement for special diseases, the average annual burden of the drug for retired employees will be further reduced to about 15,000 yuan.
After the country negotiated a substantial price reduction, the average annual drug cost of patients was about 90,000 yuan and was included in the outpatient clinic.
After reimbursement for special diseases, the average annual burden of the drug for retired employees will be further reduced to about 15,000 yuan.
It is understood that since 2001, the city has established an “outpatient special disease” system for patients with serious illnesses who require long-term outpatient treatment and high costs.
The medical expenses incurred in outpatient treatment will be reimbursed in accordance with the hospitalization reimbursement ratio and reimbursement standards .
And only one deductible line is charged within 360 days.
At present, there are 17 kinds of special diseases in outpatient clinics in this city .
Medicine Medicine Medicine Standard Standard Standard Disease Disease DiseaseThe medical expenses incurred in outpatient treatment will be reimbursed in accordance with the hospitalization reimbursement ratio and reimbursement standards .
And only one deductible line is charged within 360 days.
At present, there are 17 kinds of special diseases in outpatient clinics in this city .
At the same time, for drugs successfully negotiated by the state, for long-term outpatient treatment, high cost, and suitable for the treatment of various diseases, in order to further reduce the burden of medical expenses of the masses and facilitate the outpatient treatment of the masses, this city refers to the medical insurance outpatient clinics for urban employees and urban and rural residents.
The reimbursement level of drugs for special diseases will be paid at a fixed proportion for the trial outpatient service of 8 kinds of drugs such as "Klopevir".
The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%.
Medicine, medicine, medicineThe reimbursement level of drugs for special diseases will be paid at a fixed proportion for the trial outpatient service of 8 kinds of drugs such as "Klopevir".
The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%.
The Municipal Medical Insurance Bureau pointed out that in order to ensure the benefits of the New Policy and the people, designated medical institutions should transfer in and out of drugs according to the medical insurance drug catalog, and hold pharmaceutical management meetings in a timely manner to adjust and optimize the drug catalog of this medical institution; it should be based on functional positioning.
, Clinical needs and diagnosis and treatment capabilities, etc.
, timely provision and rational use of drugs, and the total amount of medical insurance control, medical institution drug catalog number restrictions, and drug proportions should not be used to affect new drugs, especially the provision of drugs that are successfully negotiated and renewed.
, Use, to ensure that patients can use it and use it well.
, Clinical needs and diagnosis and treatment capabilities, etc.
, timely provision and rational use of drugs, and the total amount of medical insurance control, medical institution drug catalog number restrictions, and drug proportions should not be used to affect new drugs, especially the provision of drugs that are successfully negotiated and renewed.
, Use, to ensure that patients can use it and use it well.
RAM
RAM 17 special outpatient diseases
17 special outpatient diseases Outpatient treatment of malignant tumors, kidney dialysis, anti-rejection therapy after kidney transplantation, hemophilia, aplastic anemia, anti-rejection therapy after liver transplantation, anti-rejection therapy after liver and kidney transplantation, after heart transplantation Anti-rejection therapy, anti-rejection therapy after lung transplantation, multiple sclerosis, fundus disease intraocular injection therapy, severe psychosis, type C Niemann Pick's disease, moderate to severe allergic asthma biologic therapy, pulmonary interstitial disease resistance Fibrosis treatment, targeted therapy of pulmonary hypertension, multi-drug resistant tuberculosis.
Heart, heart, heart 
